Price Chart

Executive Summary

Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering, with an additional $75M underwriter option. The filing comes on the same day the company reported strikingly positive early Phase 1/2 clinical data for vopimetostat + daraxonrasib in MTAP-deleted/RAS-mutant pancreatic cancer (92% ORR, 90% 6-mo PFS in PDAC), which it plans to advance to Phase 3. The large equity raise creates immediate and substantial dilution (~$2.72 tangible book value per share vs. $20.22 stock price), and the preliminary nature of the filing (many terms still blank) signals the offering price is not yet set — the stock may trade down on the surprise dilutive capital need despite the positive clinical readout.

Key Facts

• Tango is offering $500M of common stock via a 424B5 shelf takedown (preliminary prospectus supplement dated June 8, 2026)
• Underwriters have a 30-day option to purchase up to an additional $75M in shares
• Last sale price on June 5, 2026 was $20.22 per share; company had $2.9B market cap
• Net tangible book value as of March 31, 2026 was ~$391.5M, or $2.72 per share — new investors will face immediate and substantial dilution
• The filing is a PRELIMINARY prospectus supplement with all per-share and total dollar amounts left as blanks — pricing has not been set
• On June 8, 2026, the company also reported Phase 1/2 data for vopimetostat + daraxonrasib: 92% ORR (11/12 PDAC patients), 90% 6-month PFS, 100% DCR with no discontinuations
• Company plans to advance vopimetostat + daraxonrasib into a Phase 3 randomized-controlled trial in front-line pancreatic cancer
• Proceeds will fund general corporate purposes, including R&D, pivotal trial expenses, and potential commercialization; management says cash runway extends into 2030
• Existing shareholders (including directors and officers) are subject to a 60-day lock-up from closing

Financial Impact

At $20.22/share, $500M offering implies ~24.7M new shares (~17% dilution on 144.2M shares outstanding). Adding the full $75M greenshoe pushes potential dilution to ~28.4M shares (~20%). Net tangible book value of $2.72/share vs. $20.22 stock price indicates massive dilution for new investors.

Risk Factors

• Massive immediate dilution (~17%+ at current prices) with offering price not yet set — could be a meaningful discount to market
• Preliminary filing has all dollar amounts blank; pricing uncertainty until final prospectus is filed
• Company has no commercial supply agreement in place for Phase 3 daraxonrasib trial — supply chain risk with Revolution Medicines
• Pre-revenue biotech with significant operating losses; offering extends cash runway but increases share count permanently
• Positive Phase 1/2 data is early (n=12 for daraxonrasib arm in PDAC) — larger trials may not replicate results

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status

Related Tickers